SML1109
KU-55933
≥98% (HPLC), Ataxia telangiectasia (A-T) mutated (ATM) kinase inhibitor, powder
동의어(들):
2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-Pyran-4-one, 2-(Morpholin-4-yl)-6-(thianthren-1-yl)-4H-pyran-4-one
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C21H17NO3S2
CAS 번호:
Molecular Weight:
395.49
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
제품 이름
KU-55933, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
SMILES string
O=C1C=C(OC(=C1)c2cccc3Sc4ccccc4Sc23)N5CCOCC5
InChI
1S/C21H17NO3S2/c23-14-12-16(25-20(13-14)22-8-10-24-11-9-22)15-4-3-7-19-21(15)27-18-6-2-1-5-17(18)26-19/h1-7,12-13H,8-11H2
InChI key
XRKYMMUGXMWDAO-UHFFFAOYSA-N
Application
KU-55933 has been used as an ataxia-telangiectasia mutated (Atm) inhibitor.
Biochem/physiol Actions
KU-55933 is a very potent, specific inhibitor of Ataxia telangiectasia (A-T) mutated (ATM) kinase (IC50 = 13 nM). KU-22933 treatment sensitizes cancer cells to ionizing radiation and cytotoxic drugs. The compound KU-22933 blocks ATM-mediated phosphorylyation of p53, gH2AX, NBS1, and SMC1.
KU-55933 is a very potent, specific inhibitor of Ataxia telangiectasia (A-T) mutated (ATM) kinase.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Christianne Hoey et al.
Molecular oncology, 12(8), 1324-1341 (2018-05-31)
Recurrence of high-grade prostate cancer after radiotherapy is a significant clinical problem, resulting in increased morbidity and reduced patient survival. The molecular mechanisms of radiation resistance are being elucidated through the study of microRNA (miR) that negatively regulate gene expression.
Zhongkai Zhang et al.
Journal of experimental & clinical cancer research : CR, 39(1), 247-247 (2020-11-18)
SIRT6 has diverse roles in cells, and the role of SIRT6 in tumorigenesis is controversial. Considering the role of SIRT6 as an inducer of DNA damage repair, it might be involved in resistance to anti-cancer therapy. We evaluated the prognostic
A surveillance mechanism ensures repair of DNA lesions during zygotic reprogramming.
Ladstatter S and Kikue T K
Cell, 167(7), 1774-1787 (2016)